Details of the Drug Combination

General Information of Drug Combination (ID: DCIWNJ3)

Drug Combination Name
PMID28870136-Compound-43 Arfolitixorin
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs PMID28870136-Compound-43   DMWGV8N Arfolitixorin   DMIXMYK
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 8.7
Bliss Independence Score: 8.7
Loewe Additivity Score: 11.09
LHighest Single Agent (HSA) Score: 11.16

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
PMID28870136-Compound-43 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Ecto-5'-nucleotidase (CD73) TTK0O6Y 5NTD_HUMAN Inhibitor [3]
------------------------------------------------------------------------------------
Indication(s) of Arfolitixorin
Disease Entry ICD 11 Status REF
Colorectal cancer 2B91.Z Phase 3 [2]

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 ClinicalTrials.gov (NCT03750786) A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer (AGENT). U.S. National Institutes of Health.
3 Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304.